# Study of XL281 in Adults With Solid Tumors

> **NCT00451880** · PHASE1 · COMPLETED · sponsor: **Exelixis** · enrollment: 180 (estimated)

## Conditions studied

- Cancer
- Non-small-cell Lung Cancer
- Colorectal Cancer
- Papillary Thyroid Cancer
- Melanoma

## Interventions

- **DRUG:** XL281
- **DRUG:** famotidine

## Key facts

- **NCT ID:** NCT00451880
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2011-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451880, "Study of XL281 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00451880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*